TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists
Brief Summary: The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and adalimumab). A total of 486 medical units in metropolitan France participate in the RATIO registry. All diagnosis are retained after validation by 2 qualified infectious disease or haematologist physicians (on the basis of the standardized case report form, the hospitalisation summary, and the microbiological and radiological results). Risk factors for developing these conditions when treated by TNF-a antagonists will be identified in a case control study. Incidence of these diseases will be calculated.


Options:
A: Arm Label: Bimekizumab cohort; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Arm Label: Ustekinumab cohort; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bimekizumab, Other: Placebo | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab cohort, Placebo | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab cohort | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Ustekinumab cohort
B: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
C: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
D: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of the Albumin Dialysis MARS® Therapy in Patients With Fulminant and Subfulminant Hepatic Failure
Brief Summary: The purpose of this study is to improve the survival rate of those patients with acute fulminant hepatitis through treatment with the MARS® extra-corporal liver-purification system by:

1. Reducing the number of patients who die before a graft is available
2. Increasing the chances of survival without a liver transplant
3. Reducing the pre- and post-operative mortality in transplant patients


Options:
A: Arm Label: Ondansetron /acetylcysteine 20.25h; Type: OTHER; Interventions: Drug: Ondansetron, Drug: acetylcysteine | Arm Label: Placebo/acetylcysteine 20.25h; Type: OTHER; Interventions: Drug: acetylcysteine | Arm Label: Ondansetron/acetylcysteine 12h; Type: OTHER; Interventions: Drug: Ondansetron, Drug: acetylcysteine | Arm Label: Placebo/acetylcysteine 12h; Type: OTHER; Interventions: Drug: acetylcysteine | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Ondansetron /acetylcysteine 20.25h, Ondansetron/acetylcysteine 12h | Intervention Type: DRUG; Name: acetylcysteine; Assigned to Arm(s): Ondansetron/acetylcysteine 12h, Placebo/acetylcysteine 12h | Intervention Type: DRUG; Name: acetylcysteine; Assigned to Arm(s): Ondansetron /acetylcysteine 20.25h, Placebo/acetylcysteine 20.25h
B: Intervention Type: DEVICE; Name: Molecular Adsorbent Recirculating System (MARS®); Assigned to Arm(s): N/A
C: N/A
D: Intervention Type: DRUG; Name: acetaminophen sustained-release; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ACE Trial :Not Worn-Out Aneurism of the Abdominal Aorta Under Renal " Surgery Versus Endoprosthesis "
Brief Summary: Abdominal aortic aneurysm (AAA) is a life threatening disease. There is a consensus to propose surgical repair in patients with a reasonable operative risk when the AAA exceeds 5 cm in diameter.

The aim of the study is to compare the mortality and the occurrence of severe general, vascular and local complications in two groups of patients treated by either by open surgery or by EVAR (EndoVascular Aneurysm Repair). The main outcome criteria and the secondary endpoint are respectively the survival without severe complications and minor morbidity.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open repair | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular repair (with endograft) | Intervention Type: PROCEDURE; Name: Endovascular repair (with endograft); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Open repair; Assigned to Arm(s): 1
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Open Repair | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Repair | Intervention Type: PROCEDURE; Name: Endovascular Repair; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Standard Open Repair; Assigned to Arm(s): Arm 1
C: Arm Label: OR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Aneurysm Repair | Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular Aneurysm Repair | Intervention Type: PROCEDURE; Name: Open Aneurysm Repair; Assigned to Arm(s): OR | Intervention Type: PROCEDURE; Name: Endovascular Aneurysm Repair; Assigned to Arm(s): EVAR
D: Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: EVAR (Endovascular repair of Abdominal Aortic aneurysm) | Arm Label: Surveillance; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surveillance | Intervention Type: PROCEDURE; Name: EVAR (Endovascular repair of Abdominal Aortic aneurysm); Assigned to Arm(s): EVAR | Intervention Type: PROCEDURE; Name: Surveillance; Assigned to Arm(s): Surveillance

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ACE Trial :Not Worn-Out Aneurism of the Abdominal Aorta Under Renal " Surgery Versus Endoprosthesis "
Brief Summary: Abdominal aortic aneurysm (AAA) is a life threatening disease. There is a consensus to propose surgical repair in patients with a reasonable operative risk when the AAA exceeds 5 cm in diameter.

The aim of the study is to compare the mortality and the occurrence of severe general, vascular and local complications in two groups of patients treated by either by open surgery or by EVAR (EndoVascular Aneurysm Repair). The main outcome criteria and the secondary endpoint are respectively the survival without severe complications and minor morbidity.


Options:
A: Arm Label: OR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Aneurysm Repair | Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular Aneurysm Repair | Intervention Type: PROCEDURE; Name: Open Aneurysm Repair; Assigned to Arm(s): OR | Intervention Type: PROCEDURE; Name: Endovascular Aneurysm Repair; Assigned to Arm(s): EVAR
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Open Repair | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Repair | Intervention Type: PROCEDURE; Name: Endovascular Repair; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Standard Open Repair; Assigned to Arm(s): Arm 1
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open repair | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular repair (with endograft) | Intervention Type: PROCEDURE; Name: Endovascular repair (with endograft); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Open repair; Assigned to Arm(s): 1
D: Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: EVAR (Endovascular repair of Abdominal Aortic aneurysm) | Arm Label: Surveillance; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surveillance | Intervention Type: PROCEDURE; Name: EVAR (Endovascular repair of Abdominal Aortic aneurysm); Assigned to Arm(s): EVAR | Intervention Type: PROCEDURE; Name: Surveillance; Assigned to Arm(s): Surveillance

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ACE Trial :Not Worn-Out Aneurism of the Abdominal Aorta Under Renal " Surgery Versus Endoprosthesis "
Brief Summary: Abdominal aortic aneurysm (AAA) is a life threatening disease. There is a consensus to propose surgical repair in patients with a reasonable operative risk when the AAA exceeds 5 cm in diameter.

The aim of the study is to compare the mortality and the occurrence of severe general, vascular and local complications in two groups of patients treated by either by open surgery or by EVAR (EndoVascular Aneurysm Repair). The main outcome criteria and the secondary endpoint are respectively the survival without severe complications and minor morbidity.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open repair | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular repair (with endograft) | Intervention Type: PROCEDURE; Name: Endovascular repair (with endograft); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Open repair; Assigned to Arm(s): 1
B: Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: EVAR (Endovascular repair of Abdominal Aortic aneurysm) | Arm Label: Surveillance; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surveillance | Intervention Type: PROCEDURE; Name: EVAR (Endovascular repair of Abdominal Aortic aneurysm); Assigned to Arm(s): EVAR | Intervention Type: PROCEDURE; Name: Surveillance; Assigned to Arm(s): Surveillance
C: Arm Label: OR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Aneurysm Repair | Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular Aneurysm Repair | Intervention Type: PROCEDURE; Name: Open Aneurysm Repair; Assigned to Arm(s): OR | Intervention Type: PROCEDURE; Name: Endovascular Aneurysm Repair; Assigned to Arm(s): EVAR
D: Arm Label: 1; Type: OTHER; Interventions: Procedure: Endovascular repair | Arm Label: 2; Type: OTHER; Interventions: Procedure: Endovascular repair | Intervention Type: PROCEDURE; Name: Endovascular repair; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ACE Trial :Not Worn-Out Aneurism of the Abdominal Aorta Under Renal " Surgery Versus Endoprosthesis "
Brief Summary: Abdominal aortic aneurysm (AAA) is a life threatening disease. There is a consensus to propose surgical repair in patients with a reasonable operative risk when the AAA exceeds 5 cm in diameter.

The aim of the study is to compare the mortality and the occurrence of severe general, vascular and local complications in two groups of patients treated by either by open surgery or by EVAR (EndoVascular Aneurysm Repair). The main outcome criteria and the secondary endpoint are respectively the survival without severe complications and minor morbidity.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Open Repair | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Repair | Intervention Type: PROCEDURE; Name: Endovascular Repair; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Standard Open Repair; Assigned to Arm(s): Arm 1
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open repair | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular repair (with endograft) | Intervention Type: PROCEDURE; Name: Endovascular repair (with endograft); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Open repair; Assigned to Arm(s): 1
C: Arm Label: Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early Endovascular Repair; Type: EXPERIMENTAL; Interventions: Device: AneuRx AAA stent graft / Talent AAA stent graft | Intervention Type: DEVICE; Name: AneuRx AAA stent graft / Talent AAA stent graft; Assigned to Arm(s): Early Endovascular Repair
D: Arm Label: OR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Aneurysm Repair | Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular Aneurysm Repair | Intervention Type: PROCEDURE; Name: Open Aneurysm Repair; Assigned to Arm(s): OR | Intervention Type: PROCEDURE; Name: Endovascular Aneurysm Repair; Assigned to Arm(s): EVAR

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Atherosclerotic Disease as Measured by Carotid Intima-Media Thickness
Brief Summary: The primary purpose of this study is to compare the effects of pioglitazone, once daily (QD), versus glimepiride on the amount of thickening of the carotid artery.


Options:
A: Arm Label: Evolocumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Evolocumab, Other: lipid-lowering therapy (LLT) | Arm Label: Standard; Type: PLACEBO_COMPARATOR; Interventions: Other: lipid-lowering therapy (LLT) | Intervention Type: DRUG; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: OTHER; Name: lipid-lowering therapy (LLT); Assigned to Arm(s): Evolocumab, Standard
B: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, Drug: Hydrochlorothiazide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atenolol, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atenolol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): 2
D: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Glimepiride QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride QD

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)
Brief Summary: The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.


Options:
A: Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: Dalcetrapib (RO4607381); Type: EXPERIMENTAL; Interventions: Drug: Dalcetrapib (RO4607381) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dalcetrapib (RO4607381); Assigned to Arm(s): Dalcetrapib (RO4607381) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Rivaroxaban 2.5mg + Aspirin 100mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban 5mg + Aspirin Placebo; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Aspirin placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Arm Label: Rivaroxaban Placebo + Aspirin 100mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: Rivaroxaban placebo, Drug: Pantoprazole, Drug: Pantoprazole placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Aspirin placebo; Assigned to Arm(s): Rivaroxaban 5mg + Aspirin Placebo | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg | Intervention Type: DRUG; Name: Pantoprazole placebo; Assigned to Arm(s): Rivaroxaban 2.5mg + Aspirin 100mg, Rivaroxaban 5mg + Aspirin Placebo, Rivaroxaban Placebo + Aspirin 100mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)
Brief Summary: The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.


Options:
A: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A
C: Arm Label: 40mg Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 40mg Enoxaparin | Arm Label: 60mg Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 60mg Enoxaparin | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: DRUG; Name: 40mg Enoxaparin; Assigned to Arm(s): 40mg Enoxaparin | Intervention Type: DRUG; Name: 60mg Enoxaparin; Assigned to Arm(s): 60mg Enoxaparin | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lovastatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)
Brief Summary: The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.


Options:
A: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard of Care thromboprophylaxis | Arm Label: Interventional; Type: OTHER; Interventions: Drug: Intermediate dose thromboprophylaxis | Intervention Type: DRUG; Name: Intermediate dose thromboprophylaxis; Assigned to Arm(s): Interventional | Intervention Type: DRUG; Name: Standard of Care thromboprophylaxis; Assigned to Arm(s): Standard of Care
B: Arm Label: Intermediate dose anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: intermediate dose Enoxaparin/ unfractionated heparin | Arm Label: Standard Prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin | Arm Label: Atorvastatin 20; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin 20mg | Arm Label: Atorvastatin 20 mg Matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched placebo | Intervention Type: DRUG; Name: intermediate dose Enoxaparin/ unfractionated heparin; Assigned to Arm(s): Intermediate dose anticoagulation | Intervention Type: DRUG; Name: standard prophylactic dose Enoxaparin/ unfractionated heparin; Assigned to Arm(s): Standard Prophylaxis | Intervention Type: DRUG; Name: Atorvastatin 20mg; Assigned to Arm(s): Atorvastatin 20 | Intervention Type: DRUG; Name: Matched placebo; Assigned to Arm(s): Atorvastatin 20 mg Matched placebo
C: Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A
D: Arm Label: Therapeutic anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: Prophylactic anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Prophylactic anticoagulation, Therapeutic anticoagulation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)
Brief Summary: The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.


Options:
A: Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A
B: Arm Label: Experimental: Rosuvastatin + enoxaparin arm; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin 20mg/d for 14days | Arm Label: enoxaparin only; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin only | Intervention Type: DRUG; Name: Rosuvastatin 20mg/d for 14days; Assigned to Arm(s): Experimental: Rosuvastatin + enoxaparin arm | Intervention Type: DRUG; Name: enoxaparin only; Assigned to Arm(s): enoxaparin only
C: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Diet+pravastatin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)
Brief Summary: The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A
C: Arm Label: SANDS Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SANDS Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: FDA approved drugs to treat blood pressure and cholesterol | Intervention Type: DRUG; Name: FDA approved drugs to treat blood pressure and cholesterol; Assigned to Arm(s): SANDS Intervention Group
D: Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A

Answer: D